Inactivated Sendai virus strain Tianjin, a novel genotype of Sendai virus, inhibits growth of murine colon carcinoma through inducing immune responses and apoptosis

Journal of Translational Medicine

Volumn 11, Issue 1, 2013, Pages

  Shi, Liying ^a   Chen, Jun ^a   Zhong, Qiping ^a   Li, Mei ^a   Geng, Peng ^a   He, Jianmin ^a   Han, Zhe ^a   Sheng, Mingwei ^b   Tang, Hua ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b TIANJIN FIRST CENTRAL HOSPITAL   (China)

Author keywords

Antitumor immunity; Apoptosis; Dendritic cells; Murine colon carcinoma; Sendai virus strain Tianjin

Indexed keywords

INTERLEUKIN 6; ONCOLYTIC SENDAI VIRUS; ONCOLYTIC VIRUS; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MATURATION; COLON CARCINOMA; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTIC INFILTRATION; MOUSE; MYELOID DENDRITIC CELL; NICK END LABELING; NONHUMAN; NUCLEOTIDE SEQUENCE; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENDAI VIRUS; SURVIVAL TIME; VIRUS INACTIVATION; VIRUS STRAIN;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; DENDRITIC CELLS; FEMALE; GENOTYPE; IMMUNITY; INTERLEUKIN-6; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; MICE, INBRED BALB C; SENDAI VIRUS; SURVIVAL ANALYSIS; ULTRAVIOLET RAYS; VIRUS INACTIVATION;

EID: 84883453999     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-11-205     Document Type: Article

References (26)

1. Liu C, Sun B, An N, Tan W, Cao L, Luo X, Yu Y, Feng F, Li B, Wu M, Su C, Jiang X. Inhibitory effect of Survivin promoter-regulated oncolytic adenovirus carrying P53 gene against gallbladder cancer. Mol Oncol 2011, 5:545-554. 10.1016/j.molonc.2011.10.001, 22032823.
2. Pataer A, Fanale MA, Roth JA, Swisher SG, Hunt KK. Induction of apoptosis in human lung cancer cells following treatment with amifostine and an adenoviral vector containing wild-type p53. Cancer Gene Ther 2006, 13:806-814. 10.1038/sj.cgt.7700960, 16628227.
3. Studebaker AW, Hutzen B, Pierson CR, Russell SJ, Galanis E, Raffel C. Oncolytic measles virus prolongs survival in a murine model of cerebral spinal fluid-disseminated medulloblastoma. Neuro Oncol 2012, 14:459-470. 10.1093/neuonc/nor231, 3309851, 22307474.
4. Myers R, Greiner S, Harvey M, Soeffker D, Frenzke M, Abraham K, Shaw A, Rozenblatt S, Federspiel MJ, Russell SJ, Peng KW. Oncolytic activities of approved mumps and measles vaccines for therapy of ovarian cancer. Cancer Gene Ther 2005, 12:593-599. 10.1038/sj.cgt.7700823, 15746945.
5. Kumar R, Tiwari AK, Chaturvedi U, Kumar GR, Sahoo AP, Rajmani RS, Saxena L, Saxena S, Tiwari S, Kumar S. Velogenic newcastle disease virus as an oncolytic virotherapeutics: in vitro characterization. Appl Biochem Biotechnol 2012, 167:2005-2022. 10.1007/s12010-012-9700-1, 22644640.
6. Heinemann L, Simpson GR, Boxall A, Kottke T, Relph KL, Vile R, Melcher A, Prestwich R, Harrington KJ, Morgan R, Pandha HS. Synergistic effects of oncolyticreovirus and docetaxel chemotherapy in prostate cancer. BMC Cancer 2011, 11:221. 10.1186/1471-2407-11-221, 3129324, 21645351.
7. Murphy AM, Besmer DM, Moerdyk-Schauwecker M, Moestl N, Ornelles DA, Mukherjee P, Grdzelishvili VZ. Vesicular stomatitis virus as an oncolytic agent against pancreatic ductal adenocarcinoma. J Virol 2012, 86:3073-3087. 10.1128/JVI.05640-11, 3302313, 22238308.
8. Kaneda Y, Nakajima T, Nishikawa T, Yamamoto S, Ikegami H, Suzuki N, Nakamura H, Morishita R, Kotani H. Hemagglutinating virus of Japan (HVJ) envelope vector as a versatile gene delivery system. Mol Ther 2002, 6:219-226. 10.1006/mthe.2002.0647, 12161188.
9. Hiraoka K, Yamamoto S, Otsuru S, Nakai S, Tamai K, Morishita R, Ogihara T, Kaneda Y. Enhanced tumor-specific long-term immunity of hemagglutinating virus of Japan-mediated dendritic cell-tumor fused cell vaccination by coadministration with CpG oligodeoxynucleotides. J Immunol 2004, 173:4297-4307.
10. Yamano T, Kaneda Y, Huang S, Hiramatsu SH, Hoon DS. Enhancement of immunity by a DNA melanomavaccine against TRP2 with CCL21 as an adjuvant. Mol Ther 2006, 13:194-202. 10.1016/j.ymthe.2005.05.018, 16112911.
11. Kurooka M, Kaneda Y. Inactivated Sendai virus particles eradicate tumors by inducing immune responses through blocking regulatory T cells. Cancer Res 2007, 67:227-236. 10.1158/0008-5472.CAN-06-1615, 17210703.
12. Fujihara A, Kurooka M, Miki T, Kaneda Y. Intratumoral injection of inactivated Sendai virus particles elicits strong antitumor activity by enhancing local CXCL10 expression and systemic NK cell activation. Cancer Immunol Immunother 2008, 57:73-84. 10.1007/s00262-007-0351-y, 17602226.
13. Kawaguchi Y, Miyamoto Y, Inoue T, Kaneda Y. Efficient eradication of hormone-resistant human prostate cancers by inactivated Sendai virus particle. Int J Cancer 2009, 124:2478-2487. 10.1002/ijc.24234, 19173282.
14. Tanaka M, Shimbo T, Kikuchi Y, Matsuda M, Kaneda Y. Sterile alpha motif containing domain 9 is involved in death signaling of malignant glioma treated with inactivated Sendai virus particle (HVJ-E) or type I interferon. Int J Cancer 2010, 126:1982-1991.
15. Zhang Q, Yuan WF, Zhai GQ, Zhu SY, Xue ZF, Zhu HF, Xu XM. Inactivated Sendai virus suppresses murine melanoma growth by inducing host immune responses and down-regulating β-catenin expression. Biomed Environ Sci 2012, 25:509-516.
16. Shi LY, Li M, Yuan LJ, Wang Q, Li XM. A new paramyxovirus, Tianjin strain, isolated from common cotton-eared marmoset: genome characterization and structural protein sequences analysis. Arch Virol 2008, 153:1715-1723. 10.1007/s00705-008-0184-9, 18696006.
17. Zhou HJ, Zhang J, Chen ZY, Wang F, Li XM. Study on defective interfering particles of Paramyxovirus, Tianjin strain enhanced the immune response of the mice. Chin J Microbiol Immunol 2010, 30:1063-1067.
18. Kato T, Ueda Y, Kinoh H, Yoneyama Y, Matsunaga A, Komaru A, Harada Y, Suzuki H, Komiya A, Shibata S, Hasegawa M, Hayashi H, Ichikawa T, Yonemitsu Y. RIG-I helicase-independent pathway in sendai virus-activated dendritic cells is critical for preventing lung metastasis of AT6.3 prostate cancer. Neoplasia 2010, 12:906-914. 2978913, 21076616.
19. Faiao Flores F, Coelho PR, Toledo Arruda Neto JD, Maria Engler SS, Tiago M, Capelozzi VL, Giorgi RR, Maria DA. Apoptosis through Bcl-2/Bax and cleaved caspase up-regulation in melanoma treated by boron neutron capture therapy. PLoS One 2013, 8:e59639. 10.1371/journal.pone.0059639, 3603877, 23527236.
20. Matsushima-Miyagi T, Hatano K, Nomura M, Li-Wen L, Nishikawa T, Saga K, Shimbo T, Kaneda Y. TRAIL and Noxa are selectively upregulated in prostate cancer cells downstream of the RIG-I/MAVS signaling pathway by nonreplicating Sendai virus particles. Clin Cancer Res 2012, 18:6271-6283. 10.1158/1078-0432.CCR-12-1595, 23014529.
21. Lopez CB, Moltedo B, Alexopoulou L, Flavell RA, Moran TM. TLR-independent induction of dendritic cell maturation and adaptive immunity by negative-strand RNA virus. J Immunol 2004, 173:6882-6889.
22. Kobukai S, Kremers GJ, Cobb JG, Baheza R, Xie J, Kuley A, Zhu M, Pham W. Induction of antitumor immunity by dendritic cells loaded with membrane-translocating mucin 1 Peptide antigen. Transl Oncol 2011, 4:1-8. 10.1007/s12178-010-9068-1, 3026404, 21286372.
23. Suzuki T, Oo Chang M, Kitajima M, Takaku H. Induction of antitumor immunity against mouse carcinoma by baculovirus-infected dendritic cells. Cell Mol Immunol 2010, 7:440-446. 10.1038/cmi.2010.48, 20871626.
24. Ito T, Amakawa R, Inaba M, Hori T, Ota M, Nakamura K, Takebayashi M, Miyaji M, Yoshimura T, Inaba K, Fukuhara S. Plasmacytoid dendritic cells regulate Th cell responses through OX40 ligand and type I IFNs. J Immunol 2004, 172:4253-4259.
25. Zhao D, Chen P, Yang H, Wu Y, Zeng X, Zhao Y, Wen Y, Zhao X, Liu X, Wei Y, Li Y. Live attenuated measles virus vaccine induces apoptosis and promotes tumor regression in lung cancer. Oncol Rep 2013, 29:199-204.
26. Thirukkumaran CM, Shi ZQ, Luider J, Kopciuk K, Gao H, Bahlis N, Neri P, Pho M, Stewart D, Mansoor A, Morris DG. Reovirus as a viable therapeutic option for the treatment of multiple myeloma. Clin Cancer Res 2012, 18:4962-4972. 10.1158/1078-0432.CCR-11-3085, 22761466.